ROLE OF SERUM ONCOSTATIN M IN ASSESSMENT OF DISEASE ACTIVITY IN INFLAMMATORY BOWEL DISEASE PATIENTS

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Internal Medicine Faculty of Medicine, Alexandria University, Egypt

2 Department of Biochemistry, Faculty of Medicine, Alexandria University, Egypt

Abstract

Background: Inflammatory bowel disease (IBD) refers to chronic, inflammatory condition primarily affecting the gastrointestinal tract, with an onset typically observed during late childhood and adolescence. Ulcerative colitis and Crohn's disease are two distinct diseases that fall under the spectrum of inflammatory bowel disease (IBD) all these led in not only intestinal but also extraintestinal manifestations. The landscape of IBD management is evolving, with a discernible shift toward tailored approaches that transcend the confines of a one-size-fits-all paradigm. A critical aspect of this evolution lies in the imperative to expedite the diagnosis of IBD, as delays can impede the timely initiation of treatment and compromise patient outcomes. Hence, there is a growing interest in identifying suitable biomarkers to diagnose and assess disease activity in IBD for early diagnosis and individualized treatment modalities. Among potential target biomarker is oncostatin M, a member of the IL-6 family, has gained a lot of interest lately in the diagnosis of IBD and disease activity.
Objective: The objective of this investigation is to ascertain the utility of oncostatin M as an indicator for evaluating disease activity among individuals diagnosed with inflammatory bowel disease.

Keywords

Files

Share

How to cite

Statistics